...
首页> 外文期刊>癌と化学療法 >A case of peritoneal dissemination of gastric cancer successfully treated by irinotecan combined with cisplatin
【24h】

A case of peritoneal dissemination of gastric cancer successfully treated by irinotecan combined with cisplatin

机译:伊立替康联合顺铂成功治疗腹膜扩散性胃癌1例

获取原文
获取原文并翻译 | 示例

摘要

We report a case of a 59-year-old man with advanced gastric cancer. Distal gastrectomy with lymph node dissection (D1) was performed. Pathological staging was IV (T3N1CY1), and the operation resulted in curability C. The serum CA19-9 level before the operation was 201 U/ml, and it did not normalize 3 months after the operation. Postoperative chemotherapy (TS-1, 100 mg/day) was performed. Because the tumor markers such as CEA and CA19-9 level elevated 5 months after the operation, triweekly docetaxel therapy and TS-1 administration (days 1-14) were performed. We disbontinued this therapy after 2 courses due to adverse reactions, such as leukopenia (grade 4) and liver dysfunction (grade 2). Peritoneal dissemination was diagnosed by the appearance of ascites and thickness of the peritoneum 11 months after the operation. So the patient was treated with a biweekly combination chemotherapy of irinotecan (CPT-11 60 mg/m2) and cisplatin (CDDP 30 mg/m2). Eight courses of this therapy induced partial remission and normalization of the serum CEA level. No major adverse reaction to this therapy was observed. The partial remission and good patient's QOL were achieved during follow-up 7 months after the administration of CPT-11 plus CDDP. This case suggests that patients with recurrent peritoneal dissemination of gastric cancer could benefit from CPT-11 with CDDP combination therapy as a second-line or third-line treatment.
机译:我们报告了一例患有晚期胃癌的59岁男子。进行远端胃切除与淋巴结清扫术(D1)。病理分期为IV(T3N1CY1),手术可治愈。手术前血清CA19-9水平为201 U / ml,手术后3个月未恢复正常。进行了术后化疗(TS-1,100 mg /天)。由于肿瘤标志物(例如CEA和CA19-9水平)在术后5个月升高,因此每三周进行一次多西他赛治疗和TS-1给药(第1-14天)。由于不良反应,例如白细胞减少症(4级)和肝功能障碍(2级),我们在2个疗程后取消了该疗法的治疗。术后11个月通过腹水的出现和腹膜的厚度诊断腹膜的分布。因此,该患者接受了伊立替康(CPT-11 60 mg / m2)和顺铂(CDDP 30 mg / m2)的双周联合化疗。该疗法的八个疗程诱导了血清CEA水平的部分缓解和正常化。没有观察到对该疗法的主要不良反应。在给予CPT-11加CDDP后的7个月的随访中,部分缓解和患者的QOL良好。该病例表明,胃癌复发性腹膜扩散的患者可从CDT联合疗法作为二线或三线治疗受益于CPT-11。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号